GH Research
$8.15
+$0.05+0.62% Friday 20:00
Statistik
Harga Tertinggi Hari
9
Harga Terendah Hari
8.01
52M Tertinggi
14.99
52M Terendah
5.05
Volum
97,309
Volum Purata
44,885
Kapasiti Pasaran
546.3M
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
7NovDijangka
EPS yang dijangka
-0.246
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti GHRS. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Compass Pathways
CMPS
Kapasiti Pasaran511.54M
Mind Medicine
MNMD
Kapasiti Pasaran493.47M
ATAI Life Sciences N.V.
ATAI
Kapasiti Pasaran218.14M
Cybin
CYBN
Kapasiti Pasaran194.47M
Revive Therapeutics
RVVTF
Kapasiti Pasaran3.99M
Seelos Therapeutics
SEEL
Kapasiti Pasaran2.04M
Johnson & Johnson
JNJ
Kapasiti Pasaran399.26B
Penilaian Penganalisis
39.5$Sasaran Harga Purata
Anggaran tertinggi adalah $40.
Dari 2 penilaian dalam tempoh 6 bulan terakhir. Ini bukan cadangan pelaburan.
Beli
50%
Pegang
50%
Jual
0%
Mengenai
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Show more...
CEO
Theis Terwey
Pekerja
49
Negara
IE
ISIN
IE000GID8VI0